Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBRC-201 in Advanced Refractory Solid Tumors
NCT07145255Phase 2Recruiting
- Sponsor
- MBrace Therapeutics
- Start
- Sep 2025
- Primary completion
- Sep 2029
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of MBRC-201 in prostate cancer (PCa), breast cancer, colorectal cancer (CRC), non-small cell lung cancer (NSCLC), pancreatic cancer (PC), sponsored by MBrace Therapeutics. Started Sep 2025; status: recruiting.
02
Drugs
MBRC-201
03
Conditions
prostate cancer (PCa)breast cancercolorectal cancer (CRC)non-small cell lung cancer (NSCLC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07145255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07145255.